Indenix Suffers From FDA Hold

September 7, 2010 · Filed Under Hepatitis C · Comment 

Shares of biopharma company Indenix Pharmaceuticals, Inc. (NASDAQ: IDIX) dropped dramatically following news that the company’s two leading hepatitis C programs, IDX184 and IDX320, had been put on clinical hold by the Food and Drug Administration.  The move was made after three patients in the drug trial demonstrated signs of liver toxicity, implying that the drugs pose possible threats to users’ health.

The company, as a result, has gone from one of one of the industry’s top-performing companies to one of the quickest percentage price losers.  And, despite Indenix chairman and CEO Jean-Pierre Sommadossi’s claim that the company would “remain committed to the future potential of these drug[s],” shares plummeted 55% in premarket trading this morning.

-Michael B. Sauter

Inhibitex Completes Trial For Hep C Drug

September 1, 2010 · Filed Under Hepatitis C · Comment 

Inhibitex Inc. (NASDAQ: INHX) was up $0.16 (11.27%) this morning to $1.58 on news that the company had completed a Phase1a, single ascending dose trial of its nucleotide polymerase inhibitor, INX-189.  The drug is currently being developed for the treatment of chronic hepatitis C.  Tests of the drug have, at this point, been positive with no serious side effects.

Inhibitex Inc. is a biopharma company that specializes in the development of drugs used to prevent infective diseases, primarily shingles and hepatitis C.

-Michael B. Sauter

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed